Enzymatic Nanorobots for Combination Chemotherapy of Glioblastoma

Glioblastoma (GBM), the most common type of primary brain tumor in adults, is highly aggressive and has an extremely poor prognosis. However, traditional chemotherapy employing isolated temozolomide (TMZ) ultimately leads to chemoresistance, significantly limiting GBM treatment. In this paper, a nanorobot-mediated combination chemotherapy method was used for glioblastoma (GBM) treatment. Enzymatic nanorobots fabricated from dendritic silica nanoparticles with a small diameter of 266 nm were used to deliver the combinatorial drugs of temozolomide (TMZ) and doxorubicin (DOX), which is a novel approache for combating chemoresistance. The combination therapy promoted the apoptosis of GBM cells, and the robotic motion-induced cellular uptake of nanorobots further improved the therapeutic efficacy. Hence, combination chemotherapy using nanorobots is a promising therapeutic strategy for GBM treatment.